Uncertainty, error and informed consent to challenge trials of COVID-19 vaccines: response to Steel et al
Share this article
Click the icon of the social media platform on which you would like to share this article.
Email this article to a friend
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Other content recommended for you
- Controlled human infection with SARS-CoV-2 to study COVID-19 vaccines and treatments: bioethics in Utopia
- Better recognition for research participants: what society should learn from covid-19
- COVID-19 controlled human infection studies: worries about local community impact and demands for local engagement
- Ethics of research at the intersection of COVID-19 and black lives matter: a call to action
- Human infection challenge studies in endemic settings and/or low-income and middle-income countries: key points of ethical consensus and controversy
- Do coronavirus vaccine challenge trials have a distinctive generalisability problem?
- Payment of COVID-19 challenge trials: underpayment is a bigger worry than overpayment
- Why continuing uncertainties are no reason to postpone challenge trials for coronavirus vaccines
- UK Research Ethics Committee’s review of the global first SARS-CoV-2 human infection challenge studies
- A framework for the promotion of ethical benefit sharing in health research